Author Truemper, Lorenz

• 2008 | Journal Article | 
  ​ ​MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians​
  Bittenbring, J.; Parisot, F.; Wabo, A.; Mueller, M.; Kerschenmeyer, L.; Kreuz, M. & Truemper, L. et al.​ (2008) 
  BMC cancer, 8(116) pp. 1​-10​.​
  ​Details 

• 2011 | Journal Article | 
  ​ ​Granulocytic Sarcoma by AML M4eo (inv16) after Allogeneic Stem Cell Transplantation without Bone Marrow Involvement.​
  Zaenker, S.; Schweyer, S.; Hasenkamp, J.; Truemper, L. & Wulf, G.​ (2011) 
  Case reports in hematology, 2011 pp. 692982-1​-692982-3​.​ DOI: https://doi.org/10.1155/2011/692982 
  ​Details  DOI  PMID  PMC 

• 2019 | Journal Article
  ​ ​A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial​
  Burke, J. M; André, M.; Cheson, B. D.; Duell, J.; Nowakowski, G.; Rosenwald, A. & Salles, G. A. et al.​ (2019) 
  Blood, 134(Supplement_1) pp. 2877​-2877​.​ DOI: https://doi.org/10.1182/blood-2019-128021 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom​
  Fox, C. P; Ashaye, A. O; Shah, R.; Corman, S.; Dalal, M. & Truemper, L.​ (2019) 
  Blood, 134(Supplement_1) pp. 3482​-3482​.​ DOI: https://doi.org/10.1182/blood-2019-127289 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study​
  Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Hänel, M. & Truemper, L. et al.​ (2019) 
  Blood, 134(Supplement_1) pp. 1589​-1589​.​ DOI: https://doi.org/10.1182/blood-2019-123637 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)​
  Zettl, F.; Braulke, F.; Ziepert, M.; Viardot, A.; Kahl, C.; Prange-Krex, G. & Korfel, A. et al.​ (2019) 
  Blood, 134(Supplement_1) pp. 4073​-4073​.​ DOI: https://doi.org/10.1182/blood-2019-122948 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry​
  Hohloch, K.; Windemuth-Kieselbach, C.; Zinzani, P. L.; Cacchione, R. E.; Jurczak, W.; Suh, C. & Truemper, L. et al.​ (2019) 
  Blood, 134(Supplement_1) pp. 5263​-5263​.​ DOI: https://doi.org/10.1182/blood-2019-124192 
  ​Details  DOI 

• 2021 | Journal Article
  ​ ​Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial​
  Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Haenel, M. & Truemper, L. et al.​ (2021) 
  The Lancet Haematology, 8(4) pp. e267​-e277​.​ DOI: https://doi.org/10.1016/S2352-3026(21)00022-3 
  ​Details  DOI 

• 2021 | Journal Article
  ​ ​The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma​
  Horwitz, S. M.; Savage, K. J.; Illidge, T.; Iyer, S. P; Advani, R.; Shustov, A. R & Bartlett, N. L. et al.​ (2021) 
  Blood, 138(Supplement 1) pp. 135​-135​.​ DOI: https://doi.org/10.1182/blood-2021-145124 
  ​Details  DOI 

• 2021 | Journal Article | Research Paper
  ​ ​The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma​
  Iyer, S.; Truemper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R. & Bartlett, N. L. et al.​ (2021) 
  Clinical Lymphoma, Myeloma & Leukemia, 21(Suppl. 1) art. TCL-150​.​
  ​Details  WoS 

• 2021 | Journal Article | Research Paper | 
  ​ ​Using Instagram to Enhance a Hematology and Oncology Teaching Module During the COVID-19 Pandemic: Cross-sectional Study​
  Koenig, J. F. L.; Buentzel, J.; Jung, W.; Truemper, L. & Wurm-Kuczera, R. I.​ (2021) 
  JMIR Medical Education, 7(4) pp. e30607​.​ DOI: https://doi.org/10.2196/30607 
  ​Details  DOI 

• 2023 | Journal Article
  ​ ​Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP​
  Bewarder, M.; Kaddu-Mulindwa, D.; Kos, I. A.; Lesan, V.; Held, G.; Poeschel, V. & Thurner, L. et al.​ (2023) 
  Haematologica,.​ DOI: https://doi.org/10.3324/haematol.2022.282126 
  ​Details  DOI 

• 2023 | Journal Article
  ​ ​Drug-monitoring during ciprofloxacin prophylaxis of allogeneic stem cell transplant patients – associations with bacterial infections through a monocentric observational prospective study​
  Kaba, H. E.; Hasenkamp, J.; Tas, H.; Schulz, M.; Streit, F.; Eiffert, H. & Wulf, G. et al.​ (2023) 
  Journal of Hospital Infection,.​ DOI: https://doi.org/10.1016/j.jhin.2023.10.016 
  ​Details  DOI 

Researcher

Sort

Items per Page